HIV/AIDS Update - Tentiative approval of lamivudine, nevirapine, and stavudine fixed dose combination tablets, 150 mg/200 mg/30 mg

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: HIV/AIDS Update - Tentiative approval of lamivudine, nevirapine, and stavudine fixed dose combination tablets, 150 mg/200 mg/30 mg

You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

On September 10, 2010, the Food and Drug Administration granted tentative approval for a fixed dose combination formulation of lamivudine, nevirapine, and stavudine tablets, 150 mg/200 mg/30 mg indicated for use alone as a complete regimen or in combination with other antiretrovirals for the treatment of HIV-1 infection.  This fixed-dose combination is manufactured by Hetero Drugs Limited of Hyberdad, India

FDA's tentative approval means that although a product meets all of the safety, efficacy, and manufacturing quality standards required for marketing in the U.S., existing patents and/or proprietary issues currently prevent marketing of the product in the United States. Tentative approval, however, does qualify the product for consideration for purchase under the President's Emergency Plan for AIDS Relief, or PEPFAR program.

This Fixed Dose Combination product was reviewed for PEPFAR under the FDA guidance titled Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously approved Antiretrovirals for the Treatment of HIV developed to clarify what regulatory requirements apply to such applications, what issues might be of concern, and how these issues should be addressed. The guidance is intended to encourage sponsors to submit applications for combination and co-packaged products, and to facilitate submission of such applications to FDA.

A complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan is available on the FDA web site.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration


Manage your FDA Subscriptions:

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux